Menu

Layoffs, Restructuring at GSK

GlaxoSmithKline is eliminating 900 US jobs—most in R&D.

Dec 4, 2014
Tracy Vence

WIKIMEDIA, BRADLEY JDrug giant GlaxoSmithKline (GSK) said it will be eliminating 900 US employees in restructuring its research and development (R&D) efforts, among other things, FierceBiotech reported. But not all 900 will be laid off, GSK said, noting some employees may be relocated to other facilities. The firm’s Research Triangle Park, North Carolina, facility will be hit hardest by the changes.

“The details are still unfolding, but we expect as part of this restructure existing roles will be lost in our US R&D and commercial organizations by the end of 2015,” a GSK spokesperson told The Wall Street Journal’s Pharmalot.

“Some R&D roles will be relocated to the Philadelphia area, and some staff will be offered relocation,” GSK told Fierce. “Cuts are not being made across the board but are strategic, focused changes to allow GSK to operate more efficiently. . . . This is a rescaling of work to reflect market forces that were anticipated but that have accelerated and are affecting the entire industry.”

Hints at changes to come at the pharmaceutical firm came earlier this year. In April, GSK and Novartis agreed to swap assets totaling more than $20 billion. Novartis said it would buy GSK’s oncology business, while GSK agreed to purchase Novartis’s vaccines division.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!